

CareFusion Launches New Alaris® System For Canada

New Version of Guardrails® Suite MX Safety Software Helps Improve Medication Safety

TORONTO, June 16, 2014— CareFusion (NYSE:CFN), a leading global medical technology company, today announced the Canadian launch of the Alaris® System to help improve IV medication safety.

The new version of Guardrails® Suite MX safety software contains a number of improvements that help clinicians ensure the correct dosing and rate of infusions by providing better visibility to any programmed value that exceeds a Guardrails limit. In addition, the new version for Canada includes enhanced protection for infant and pediatric infusions where weight is a critical factor in drug and fluid dosages and protection. Support for million unit dosing and nanogram precision of up to five digits for concentration limits are supported for adults, children and infants. The new system provides device notification of non-Guardrails programming and can alert the clinician when there is an unintentional closed clamp on a secondary infusion when used in conjunction with CareFusion secondary infusion sets.

“Patient safety is at the core of this latest release, with enhanced protection against medication errors and improved workflow to increase safety software compliance” said J.C. Kyrillos, senior vice president and general manager of Infusion for CareFusion. “The new release provides additional therapy-specific dosing, enhanced messaging for clinicians and earlier notifications of certain alarm conditions, reaffirming our position as a market and clinical leader.”

The Hospital for Sick Children (SickKids) in Toronto is the first hospital to adopt the new Guardrails Suite MX safety software.

“These recent enhancements support neonatal and pediatric IV therapy and medication administration,” said Helen Edwards, Director of Clinical Informatics and Technology Assisted Program at SickKids. “CareFusion provided support to front-line staff throughout the implementation process, which involved upgrading more than 2,000 pump units used across the entire hospital — in all inpatient, outpatient and surgical settings.”

The Alaris System is one of the most comprehensive IV medication safety systems available. Built on a modular platform, the Alaris System with Guardrails Suite MX safety software provides safety beyond just dose error reduction. It is the only smart pump that can protect every infusion, including intermittents and all infusion modalities, including large volume pump, PCA and syringe. The new Alaris System received approval from Health Canada and is currently in Limited Commercial Release.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com

For more information on BD, please visit bd.com.

Troy Kirkpatrick

858 617 2361

[Email Troy](#)

This document is intended for audiences outside of the U.S.

*Products referred to in this release may not be available in all countries. Contact your local CareFusion office to check the availability and confirm prescribing information.

